RDY

Peers: TEVA JNJ NVS ABBV PFE MRK BMY LLY SNY GSK

| Held by: VWO SPEM AVEM VXUS DFAE VEU DFEM DFAX DFEV IEQ

Index	-	P/E	17.56	EPS (ttm)	0.78	Insider Own	0.01%	Shs Outstand	834.63M	Perf Week	4.51%
Market Cap	11.39B	Forward P/E	22.27	EPS next Y	0.61	Insider Trans	0.00%	Shs Float	832.34M	Perf Month	-4.13%
Enterprise Value	11.26B	PEG	-	EPS next Q	0.16	Inst Own	13.12%	Short Float	1.48%	Perf Quarter	-8.00%
Income	650.03M	P/S	2.87	EPS this Y	-12.73%	Inst Trans	4.56%	Short Ratio	9.76	Perf Half Y	-7.00%
Sales	3.97B	P/B	2.76	EPS next Y	-11.36%	ROA	11.67%	Short Interest	12.30M	Perf YTD	-2.56%
Book/sh	4.96	P/C	12.39	EPS next 5Y	-2.16%	ROE	17.72%	52W High	16.17 -15.40%	Perf Year	-9.34%
Cash/sh	1.10	P/FCF	-	EPS past 3/5Y	28.16% 19.33%	ROIC	15.22%	52W Low	12.26 11.58%	Perf 3Y	26.64%
Dividend Est.	0.10 (0.75%)	EV/EBITDA	11.99	Sales past 3/5Y	10.20% 9.35%	Gross Margin	52.69%	Volatility	2.47% 1.49%	Perf 5Y	-3.74%
Dividend TTM	0.09 (0.67%)	EV/Sales	2.84	EPS Y/Y TTM	1.13%	Oper. Margin	18.00%	ATR (14)	0.25	Perf 10Y	56.09%
Dividend Ex-Date	Jul 25, 2025	Quick Ratio	1.38	Sales Y/Y TTM	6.69%	Profit Margin	16.38%	RSI (14)	51.79	Recom	2.82
Dividend Gr. 3/5Y	5.27% 3.13%	Current Ratio	1.88	EPS Q/Q	-18.89%	SMA20	0.57%	Beta	0.35	Target Price	14.58
Payout	8.90%	Debt/Eq	0.18	Sales Q/Q	-1.04%	SMA50	-1.11%	Rel Volume	1.45	Prev Close	13.71
Employees	27811	LT Debt/Eq	0.03	Earnings	Jan 20 AMC	SMA200	-3.70%	Avg Volume	1.26M	Price	13.68
IPO	Apr 11, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.99% 2.58%	Trades		Volume	1,824,462	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Upgrade	HSBC Securities	Hold → Buy	$16.90
Dec-19-24	Downgrade	Nomura	Buy → Neutral
Jan-11-24	Downgrade	Jefferies	Buy → Underperform
Aug-29-23	Downgrade	HSBC Securities	Buy → Hold
May-18-23	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-17-23	Upgrade	BofA Securities	Neutral → Buy
Jan-30-23	Initiated	JP Morgan	Underweight
Nov-14-22	Downgrade	Credit Suisse	Neutral → Underperform
Jan-03-22	Resumed	BofA Securities	Neutral
Jul-27-21	Downgrade	Credit Suisse	Outperform → Neutral
Feb-02-21	Upgrade	Barclays	Equal Weight → Overweight	$56 → $70
Sep-18-20	Upgrade	Investec	Sell → Hold
Sep-18-20	Upgrade	BofA Securities	Neutral → Buy
Jan-28-20	Downgrade	CLSA	Buy → Outperform
Jan-27-20	Downgrade	CLSA	Buy → Outperform
Jan-09-20	Upgrade	Citigroup	Sell → Buy
Nov-04-19	Downgrade	BofA/Merrill	Buy → Neutral
Sep-04-19	Upgrade	Credit Suisse	Underperform → Outperform
Jul-01-19	Upgrade	Macquarie	Neutral → Outperform
Jun-20-19	Initiated	Deutsche Bank	Hold

Show Previous Ratings

Jan-22-26 09:26AM	Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y (Zacks)
Jan-21-26 12:41PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
12:14PM	Dr. Reddy's Laboratories Q3 Earnings Call Highlights (MarketBeat)
11:22AM	Doctor Reddy's: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-18-26 07:30AM	Trump in Davos, Netflix and Intel results on deck earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Loading…
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps up: What to watch this week (Yahoo Finance)
Jan-14-26 08:49AM	Dr. Reddys Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S. (Business Wire)
Dec-09-25 04:53AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's (Zacks)
Dec-08-25 08:23AM	3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape (Zacks)
Dec-02-25 08:00AM	Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies (Business Wire)
Nov-28-25 11:30AM	Bausch (BHC) Down 5.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Nov-07-25 11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
Oct-27-25 11:32AM	Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
11:00AM	Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
03:53PM	Loading…
Oct-24-25 03:53PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Oct-22-25 12:00PM	Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025 (Business Wire)
Oct-09-25 08:57AM	ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering (Zacks)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-30-25 09:15AM	Here's How Alvotech is Expanding its Portfolio Beyond Immunology (Zacks)
Sep-29-25 10:04AM	Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? (Zacks)
Sep-23-25 12:19PM	Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play? (Zacks)
Sep-22-25 10:32AM	Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Sep-18-25 11:25AM	Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? (Zacks)
09:33AM	Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth (Zacks)
Sep-11-25 09:48AM	Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? (Zacks)
Sep-09-25 09:09AM	ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell? (Zacks)
Aug-18-25 08:16AM	Extrovis AG and Dr. Reddys announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. (GlobeNewswire)
Jul-30-25 10:11AM	Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-24-25 11:21AM	Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
01:57PM	Loading…
Jul-23-25 01:57PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
01:46PM	Dr. Reddys Q1FY26 Financial Results (Business Wire)
11:20AM	Dr. Reddy's Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement (Insider Monkey)
Jul-18-25 05:08AM	New Strong Sell Stocks for July 18th (Zacks)
Jun-17-25 11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
09:15AM	Roku (ROKU) Surges 10.4%: Is This an Indication of Further Gains? (Zacks)
07:38AM	EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last? (Zacks)
Jun-05-25 08:59PM	HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold (Insider Monkey) +5.29%
11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
07:00AM	Alvotech and Dr. Reddys Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) (Business Wire)
May-12-25 05:00PM	Dr Reddy's Laboratories Ltd (RDY) Full Year 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 06:36PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
02:53PM	Dr. Reddys Q4 & Full Year FY25 Financial Results (Business Wire)
May-04-25 07:42AM	Wall Street Week Ahead (Seeking Alpha)
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
Apr-24-25 01:11PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Apr-21-25 10:23AM	Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? (Zacks)
Apr-16-25 04:38AM	Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals (Zacks)
Apr-15-25 07:15AM	3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes (Zacks)
Apr-14-25 10:13AM	Dr. Reddy's Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires (Insider Monkey)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-03-25 02:16PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Mar-31-25 09:30AM	RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar (Zacks)
Mar-27-25 11:47AM	Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara Biosimilar, and BAT2506, a Proposed Simponi Biosimilar, for Southeast Asia (PR Newswire)
Mar-19-25 11:13AM	FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review (Zacks)
Mar-18-25 08:35AM	Alvotech and Dr. Reddys Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (Business Wire)
Mar-14-25 10:45AM	Dr. Reddys announces recall of Levetiracetam 0.75% Sodium Chloride injection (TipRanks)
Mar-13-25 10:40AM	Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag (Business Wire)
Mar-01-25 02:54PM	Is Dr. Reddy's Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-27-25 08:48AM	Is Dr. Reddys Laboratories Limited (RDY) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
Feb-07-25 04:43AM	Dr Reddys and Shanghai Henlius sign agreement for HLX15 (Pharmaceutical Technology)
Feb-06-25 07:51AM	Dr. Reddys enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe (Business Wire)
06:40AM	Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. (PR Newswire)
Jan-24-25 02:03AM	Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Jan-23-25 02:02PM	Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business (Benzinga) -6.23%
01:41PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
12:35PM	Dr. Reddys Q3 & 9MFY25 Financial Results (Business Wire)
Dec-21-24 07:15AM	Dr. Reddys Laboratories Allocates Equity Shares to Employees (TipRanks)
Dec-03-24 06:52AM	Dr. Reddys Boosts Workforce with Equity Allotment (TipRanks)
Nov-30-24 04:24PM	Why Dr. Reddy's Laboratories Limited (RDY) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
06:47AM	Dr. Reddys Launches Innovative Cancer Drug in India (TipRanks)
Nov-29-24 07:34AM	Dr. Reddy's Laboratories introduces Toripalimab in India for nasopharyngeal carcinoma (Pharmaceutical Business Review)
Nov-28-24 06:15AM	Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma (Business Wire)
Nov-26-24 08:07AM	Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market (Business Wire)
Nov-20-24 08:30AM	Dr. Reddys Gains Strong Rating Amid Robust Growth (TipRanks)
Nov-07-24 06:31AM	Dr. Reddys Labs Releases Unaudited Financial Results (TipRanks)
Nov-06-24 02:15AM	Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-05-24 02:23PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
09:59AM	Dr. Reddys Q2 & H1FY25 Financial Results (Business Wire)
Oct-29-24 07:59PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Oct-25-24 07:40AM	Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year (Business Wire)
Oct-14-24 09:47AM	Dr. Reddys Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month (Business Wire)
Oct-09-24 07:57AM	Dr. Reddys Subsidiary Triumphs in CAR-T Cell Therapy Trial (TipRanks)
03:58AM	Dr. Reddys Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years (Insider Monkey)
Oct-08-24 11:32AM	Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for Indias First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma (Business Wire)
06:27AM	Dr. Reddys Unveils New Danish Subsidiary (TipRanks)
Oct-02-24 11:10AM	Dr. Reddys signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries (Business Wire)
Oct-01-24 07:14AM	Dr. Reddys Acquires Global NRT Leader Nicotinell (TipRanks)
Sep-28-24 12:57PM	Dr. Reddys Expands Portfolio with $620M Investment (TipRanks)
Aug-21-24 06:13AM	Dr Reddys, Aurigene and Kainomyx to co-develop anti-malarials (Pharmaceutical Technology)
Aug-20-24 02:42PM	Dr. Reddys Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug (Business Wire)
Jul-29-24 01:01PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
11:55AM	Dr. Reddys Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar (Business Wire)
10:07AM	Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
Jul-27-24 09:51AM	Dr. Reddys Q1FY25 Financial Results (Business Wire)
Jun-27-24 10:25AM	Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug (Zacks)
Jun-26-24 03:31PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
11:26AM	Dr. Reddys to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business (Business Wire)

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Dr. Reddy's Laboratories Ltd. ADR

Upgrade your FINVIZ experience